Literature DB >> 3949849

Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.

F Wingen, T Eichmann, C Manegold, B Krempien.   

Abstract

This report is concerned with therapeutic studies utilizing new bisphosphonic acids on tumor-induced osteolytic metastases. The bone metastases on SD rats were induced by intraarterial and intraosseous transplantation of Walker carcinosarcoma 256 B ascites cells. The treatment was carried out using disodium-3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP), diglycidyl-[3-(3, 3-bisphosphono-3-hydroxy-propylamino)-2-hydroxypropyl-]urazol++ +-Na2 (DDU) and 1,2,4-triglycidylurazol (TGU). The extent of bone metastases was determined by X-ray on the 5th and 10th days following tumor inoculation, as well as both microradiographically and histologically upon termination of the experiment. High dose DDU produced a clear reduction of the tumor osteolysis, but these positive results were surpassed using APD. The best results were achieved by pretreatment with APD 24 h prior to tumor inoculation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3949849     DOI: 10.1007/bf00402773

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

2.  Bone metastases studied by experimental models.

Authors:  C S Galasko
Journal:  Schweiz Med Wochenschr       Date:  1981-12-05

3.  Effects of disodium etidronate in murine tumor models.

Authors:  A Guaitani; N Polentarutti; S Filippeschi; L Marmonti; F Corti; C Italia; G Coccioli; M G Donelli; A Mantovani; S Garattini
Journal:  Eur J Cancer Clin Oncol       Date:  1984-05

4.  [Diphosphonates in the treatment of bone metastases].

Authors:  A Jung; H Fleisch
Journal:  Schweiz Med Wochenschr       Date:  1981-12-05

5.  Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma.

Authors:  F Wingen; D Schmähl
Journal:  Arzneimittelforschung       Date:  1985

6.  Preclinical evaluation of the anti tumour activity of new epoxyde derivatives.

Authors:  G Atassi; P Dumont; U Fisher; M Zeidler; M Budnowski
Journal:  Cancer Treat Rev       Date:  1984-03       Impact factor: 12.111

7.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

8.  The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis.

Authors:  C S Galasko; A W Samuel; S Rushton; E Lacey
Journal:  Br J Surg       Date:  1980-07       Impact factor: 6.939

9.  Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo.

Authors:  H Fleisch; R G Russell; M D Francis
Journal:  Science       Date:  1969-09-19       Impact factor: 47.728

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  15 in total

1.  Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.

Authors:  Andreas A Kurth; Soo-Zin Kim; Marie Shea; Frieder Bauss; Wilson C Hayes; Ralph Müller
Journal:  J Bone Miner Metab       Date:  2007-02-26       Impact factor: 2.626

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 3.  Antitumour effects of bisphosphonates: first evidence and possible mechanisms.

Authors:  I J Diel
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  In vivo and in vitro investigations on biological effects of aromatic bis-(2-chloroethyl)amino-bisphosphonic acids, new agents proposed for chemotherapy of bone tumors: cytostatic activity in rat osteosarcoma; toxicity and genotoxicity in liver and bone marrow; mutagenicity in S. typhimurium.

Authors:  B L Pool; M Berger; J R Schlehofer; F Wingen
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

5.  Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agents.

Authors:  F Wingen; B L Pool; P Klein; T Klenner; D Schmähl
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

6.  Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?

Authors:  T Klenner; F Wingen; B K Keppler; B Krempien; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 7.  Rat models of bone metastases.

Authors:  Stéphane Blouin; Michel Félix Baslé; Daniel Chappard
Journal:  Clin Exp Metastasis       Date:  2006-05-03       Impact factor: 5.150

Review 8.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

9.  Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat.

Authors:  T Klenner; F Wingen; B Keppler; P Valenzuela-Paz; F Amelung; D Schmähl
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

10.  The value of bone marrow examination for tumor staging in breast cancer.

Authors:  C Manegold; B Krempien; M Kaufmann; K Schwechheimer; G Schettler
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.